← Leaderboards
Mitchell S. Cairo
Columbia University Health Sciences
$6,247,536
Attributed
$6,247,536
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $924.5K · FY2012–25$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
FDA$6,024,561 · 3
NIH$721,675 · 7
By mechanism
R01$6,024,561 · 3
U54$498,700 · 1
R21$163,500 · 1
R13$59,475 · 5
Top collaborators
- Timothy P Cripe2 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Adi Cohen$3,447,742
- Steven M Kawut$28,347,465
- Peter D Canoll$11,470,200
- Margaret T Lee$2,047,952
- Emily Margaret Mace$6,560,188
Others in their field
Top investigators on “S Lymphoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$171,980,034
- Richard L Schilsky · University Of Chicago$120,036,663
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$113,682,224
- Ronald T Mitsuyasu · University Of California Los Angeles$103,553,444
- Monica M Bertagnolli · Strang Cancer Prevention Center$61,393,123
- Charles A Coltman · Southwest Oncology Group$55,198,633
Research focus
S LymphomaChildhoodClinical ResearchNatural Killer CellsNew YorkGenomicsImmuneSmall MoleculeBaseMalignant NeoplasmsResearch PersonnelInternationalFuture GenerationsImmunotherapyGermanyInvestigationDiagnosisBiological ProductsClinical TrialsCollaborationsBiologyCommunicationFutureEnvironment
Grant awards (23)
A Randomized Study of Maternal Donor Derived CMV Cytotoxic T-Lymphocytes (CTLs) and Valganciclovir vs Valganciclovir in Neonates With Moderate/Severe Maternal Acquired CMV Infection$324,998
R01 · FY2025 · FD · contact PI
A Randomized Study of Maternal Donor Derived CMV Cytotoxic T-Lymphocytes (CTLs) and Valganciclovir vs Valganciclovir in Neonates With Moderate/Severe Maternal Acquired CMV Infection$649,999
R01 · FY2023 · FD · contact PI
Novel Immunomodulation and Facilitation of âSuppression Proofâ CAR NK cell against Ewing sarcoma$253,700
U54 · FY2023 · CA
CMV, ADV and EBV Viral Cytotoxic T-Lymphocytes Generated by a Novel Cytokine Capture System in Children,Adolescents and Young Adults with Refractory Viral Infection and T-Cell Immunodeficiency$428,718
R01 · FY2022 · FD · contact PI
Overcoming Immunological Tumor Microenvironment Resistance in Ewing Sarcoma$245,000
U54 · FY2022 · CA
Seventh International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma$4,475
R13 · FY2022 · CA · contact PI
CMV, ADV and EBV Viral Cytotoxic T-Lymphocytes Generated by a Novel Cytokine Capture System in Children,Adolescents and Young Adults with Refractory Viral Infection and T-Cell Immunodeficiency$425,145
R01 · FY2021 · FD · contact PI
Phase 2 Defibrotide PPX in High Risk SCD Pts w/MAC&Haplo AlloSCT IND127812 9-3-15$499,999
R01 · FY2020 · FD · contact PI
CMV, ADV and EBV Viral Cytotoxic T-Lymphocytes Generated by a Novel Cytokine Capture System in Children, Adolescents and Young Adults with Refractory Viral Infection and T-Cell Immunodeficiency$424,470
R01 · FY2020 · FD · contact PI
Phase 2 Defibrotide PPX in High Risk SCD Pts w/MAC&Haplo AlloSCT IND127812 9-3-15$499,998
R01 · FY2019 · FD · contact PI
CMV, ADV and EBV Viral Cytotoxic T-Lymphocytes Generated by a Novel Cytokine Capture System in Children, Adolescents and Young Adults with Refractory Viral Infection and T-Cell Immunodeficiency$423,128
R01 · FY2019 · FD · contact PI
Phase 2 Defibrotide PPX in High Risk SCD Pts w/MAC&Haplo AlloSCT IND127812 9-3-15$499,998
R01 · FY2018 · FD · contact PI
Sixth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma$10,000
R13 · FY2018 · CA · contact PI
Phase 2 Defibrotide PPX in High Risk SCD Pts w/MAC&Haplo AlloSCT IND127812 9-3-15$249,113
R01 · FY2017 · FD · contact PI
Ph2 of T-Cell Depl Familial Haploidentical SCT for tx Hi-Risk Sickle Cell Anemia$399,569
R01 · FY2015 · FD · contact PI
Ph2 of T-Cell Depl Familial Haploidentical SCT for tx Hi-Risk Sickle Cell Anemia$399,560
R01 · FY2014 · FD · contact PI
Ph2 of T-Cell Depl Familial Haploidentical SCT for tx Hi-Risk Sickle Cell Anemia$399,869
R01 · FY2013 · FD · contact PI
1st Annual Tandem ASPHO/PBMTC Educational Mtg: New Frontiers in Pediatric AlloSCT$5,000
R13 · FY2013 · CA · contact PI
Ph2 of T-Cell Depl Familial Haploidentical SCT for tx Hi-Risk Sickle Cell Anemia$399,997
R01 · FY2012 · FD · contact PI
Fourth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgk$15,000
R13 · FY2012 · CA · contact PI
Nonablative AlloSCT in Refractory Autoimmune Disease$81,750
R21 · FY2003 · AR
First Int'l Symposium on Childhood and Adolescent NHL$25,000
R13 · FY2003 · CA
Nonablative AlloSCT in Refractory Autoimmune Disease$81,750
R21 · FY2002 · AR